Sanofi is to take on Boehringer Ingelheim's consumer health division in exchange for ... Sanofi will gain access to a number of leading brands across different categories, including digestion ...

Sanofi ( NASDAQ: SNY) has entered a share purchase agreement in relation to the sale of a 50% controlling stake in Opella, ...

The pharma signed an agreement handing PE firm CD&R a 50% stake in its Capella unit. Elsewhere, Gilead and Ultragenyx secured ...

In its third-quarter results update, Sanofi said the consumer health unit – which owns brands like allergy therapies Allegra and Xyzal, irritable bowel syndrome product Buscopan, painkiller ...

Sanofi is closer to selling a 50% controlling stake in the consumer health business, Opella to private equity Clayton ...

Sanofi and CD&R have signed a share purchase agreement for the sale of a 50% stake in the consumer health business.

Sanofi Consumer Healthcare India has reported 1% rise in net profit to Rs 46.35 crore on a 6.8% increase in net sales to Rs 170.70 crore in Q3 FY25 as compared with Q3 FY24.

Sanofi SAN-1.58%decrease; red down pointing triangle forecast stronger earnings growth this year and said it planned to launch a $5.2 billion share buyback. The French pharmaceutical company said ...

In 2022, Sanofi saw strong growth in sales of analgesics as consumers sought to self-treat mild cases of COVID-19, flus and colds. The company has been strategically divesting non-core brands, and the ...

Sanofi’s sale of its $17bn consumer health business Opella just advanced a step closer, after the drugmaker signed a share purchase agreement with buyer Clayton Dubilier & Rice (CD&R).